

HOUSE RESEARCH

Bill Summary

FILE NUMBER: H.F. 2446
Version: As introduced

DATE: March 4, 2014

Authors: Simonson

Subject: Synthetic drugs

Analyst: Jeff Diebel

This publication can be made available in alternative formats upon request. Please call 651-296-6753 (voice); or the Minnesota State Relay Service at 1-800-627-3529 (TTY) for assistance. Summaries are also available on our website at: www.house.mn/hrd/.

Overview

This bill contains the legislative recommendations from the House's Select Committee on Controlled Substances and Synthetic Drugs.

Section

- 1** **Drug.** Expands the definition of "drug" in the chapter of law addressing pharmacy matters. Drug would include any compound, substance, or derivative which is not approved for human consumption by the United States Food and Drug Administration or specifically permitted by Minnesota law, and when introduced into the body, induces an effect substantially similar to that of a Schedule I or Schedule II controlled substance regardless of whether the substance is marketed for the purpose of human consumption. This broader definition will give the Board of Pharmacy more power to regulate synthetic drugs.
- 2 – 3** **Cease and desist orders.** Empowers the Board of Pharmacy to issue cease and desist orders to businesses that sell synthetic drugs. The Board would have the authority to order a business to cease selling synthetic drugs that, in the Board's opinion, are a banned substance or analog of Schedule I or Schedule II drugs. An affected business would be entitled to an administrative hearing to challenge the Board's order. The Board's authority is patterned after the Commissioner of Commerce's cease and desist authority (Minn. Stat, ch. 45).
- 4** **Exceptions.** Clarifies that pharmacists and retailers may not sell synthetic drugs and are subject to the authority of the Board of Pharmacy if they do so.
- 5** **Prohibited acts.** Expressly prohibits the sale of synthetic drugs that induce the same or substantially similar effect as scheduled controlled substances.

Section

- 6** **Drugs, adulteration.** Specifies that a drug is considered adulterated if it was manufactured at a facility not licensed pursuant to the standards established in chapter 151 (pharmacy).
- 7** **Drugs, misbranding.** Specifies that a drug is deemed misbranded if the package does not include a statement of ingredients.
- 8** **Expedited scheduling of additional substances.** Strikes the statutory requirement that the Board of Pharmacy's emergency drug scheduling decisions must be ratified by the Legislature to make the Board's actions final. As a check on the Board's emergency rulemaking authority, the Legislature established a legislative ratification requirement. The Legislature would retain the authority to overturn a scheduling decision by the Board of Pharmacy with regard to a specific compound.
- Removes the sunset on the Board of Pharmacy's emergency drug scheduling authority. The Board's authority is set to expire on August 1, 2014.
- 9** **Prosecution training; expert witness compensation.** Funds a pilot project that will (1) train prosecutors in the best practices of prosecuting synthetic drug cases and (2) pay expert witnesses in synthetic drug investigations and trials.
- 10** **BCA appropriation.** Appropriates funds to the Bureau of Criminal Apprehension for analyzing and testing synthetic drugs.
- 11** **Public awareness campaign; appropriation.** Appropriates funds for the Commissioner of Education to formulate and implement an educational awareness campaign on the dangers of synthetic drug use. The education campaign should be designed to reach a broad audience but contain targeted messages for students.
- 12** **Board of Pharmacy; appropriation.** Appropriates funds to the Board of Pharmacy to implement the Board's cease and desist authority and to aid prosecutors with expert guidance in synthetic drug cases.